Oslo, Norway, 29 January 2018

The Board of Directors of Nordic Nanovector ASA ("Nordic Nanovector" or the
"Company") has on 29th of January 2018 decided to grant 216 550 Performance
Share Units ("PSUs") to employees in accordance with the authorisation granted
at the Extraordinary General Meeting held on 20 December 2017 (the "EGM").

The terms and conditions of the PSUs, which are part of the Company's new long
-term incentive plan for employees, are described in the Board of Directors'
amended proposal for share based incentive program, available in English and
Norwegian at www.nordicnanovector.com/investors-and-media/corporate
-governance/general-meetings.

The PSUs are granted without consideration. The PSU are non-transferable and
will vest three years after the date of grant subject to satisfaction of the
applicable vesting conditions described in appendix 3 to the summons to the EGM
and the PSU agreements. Each vested PSUs will give the holder the right to
acquire one share in the Company at an exercise price corresponding to the par
value of the shares being NOK 0.20.

In accordance with the resolution at the EGM the PSUs and the options previously
granted are secured by a corresponding number of free-standing warrants. The
sole purpose of the warrants is to ensure delivery of shares in the Company upon
exercise of the PSUs and options. The warrants do not give the PSU holders or
the option holders a right to subscribe for any additional shares in the
Company.

Primary insiders that were granted PSUs on 29th of January 2018 have the
following holding of PSUs, options and shares in the Company following such
grant:

Luigi Costa, CEO holds 30,000 PSUs, 1,338,106 options and 81,115 shares

Rosemarie Corrigan, CQO holds 20,000 PSUs, 0 options and 0 shares

Jostein Dahle, CSO holds 12,000 PSUs, 150,000 options and 204,958 shares
including shares to related party

Anniken Hagen, CTOO holds 5,000 PSUs, 177,000 options and 63,858 shares

Rita Dege, CHRO holds 6,500 PSUs, 67,000 options and 4,754 shares

Tone Kvåle, CFO holds 20,000 PSUs, 315,000 options and 179,608 shares including
shares to related party

Marco Renoldi, COO holds 25,000 PSUs, 464,137 options and 74,000 shares

Lisa Rojkjaer, CMO holds 25,000 PSUs, 375,000 options and 4,186 shares

The PSUs allocated to the management of the Company is in accordance with the
amended Board of Director's declaration on salaries and other remuneration to
the senior executive management, as approved by the Company's EGM. The total
number of outstanding options and PSUs are now 3 482 843 and 216 550
respectively. Subject to all vesting conditions being fulfilled exercise of the
options and PSUs would create a 7.1 % dilution of the outstanding shares on a
fully diluted basis.

For further information, please contact:

Ludvik Sandnes, Chairman

Phone: +47 907 43 017

E-mail: lsandnes@nordicnanovector.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC)
designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an
indication with substantial unmet medical need, representing a growing market
forecast to be worth nearly USD 20 billion by 2024. The company aims to rapidly
develop Betalutin®, alone and in combination with other therapies, for the
treatment of major types of NHL, targeting first regulatory submission in
relapsed/refractory follicular lymphoma in 2019. Nordic Nanovector intends to
retain marketing rights and to actively participate in the commercialisation of
Betalutin® in core markets. The company is also advancing a pipeline of ARCs and
other immunotherapies for multiple cancer indications. Further information about
the company can be found at www.nordicnanovector.com

This information is subject to duty of disclosure pursuant to Section 4-2 of the
Norwegian Securities Trading Act.

